Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...

Influenza, COVID-19 and RSV are staples of the winter cold and flu season, but the measles, whooping cough and norovirus are ...

Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu ...

which is also approved for maternal use to prevent RSV in newborns and infants. William Blair estimates that mResvia could eventually capture around 27% of the US market, which would translate to ...

Nonetheless, with COVID-19, seasonal influenza, and RSV, even an average respiratory season can place substantial strain on the health care system. It is crucial for Maine clinicians to stay up to ...